Besides EGFR gene mutations and ALK gene rearrangements, which should be tested upfront in all patients with advanced nonsquamous NSCLC, other actionable targets have been recently identified and new genomic-driven agents are expanding the therapeutic arsenal against NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.